S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

Lucid Diagnostics Stock Price, News & Analysis (NASDAQ:LUCD)

$1.54
+0.07 (+4.76%)
(As of 12/4/2023 ET)
Compare
Today's Range
$1.47
$1.54
50-Day Range
$1.16
$1.54
52-Week Range
$1.04
$2.00
Volume
74,103 shs
Average Volume
64,765 shs
Market Capitalization
$68.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Lucid Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
111.0% Upside
$3.25 Price Target
Short Interest
Healthy
1.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$5,821 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.26) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

569th out of 952 stocks

Surgical & Medical Instruments Industry

62nd out of 89 stocks


LUCD stock logo

About Lucid Diagnostics Stock (NASDAQ:LUCD)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

LUCD Stock Price History

LUCD Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Earnings Preview For Lucid Diagnostics
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Q2 2023 Lucid Diagnostics Inc Earnings Call
Lucid Diagnostics Inc.
8-K: Lucid Diagnostics Inc.
Q1 2023 PAVmed Inc Earnings Call
Where Lucid Diagnostics Stands With Analysts
See More Headlines
Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2022
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/12/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUCD
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.25
High Stock Price Target
$4.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+111.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-56,170,000.00
Net Margins
-4,153.13%
Pretax Margin
-3,784.27%

Debt

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$0.59 per share

Miscellaneous

Free Float
42,523,000
Market Cap
$68.79 million
Optionable
Not Optionable
Beta
1.86
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Lishan Aklog M.D. (Age 57)
    Chairman & CEO
  • Dr. Sanford D. Markowitz M.D.
    Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor Board
  • Dr. Joseph Willis M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Dr. Amitabh Chak M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Richard D. Yazbeck
    Chief Technology Officer
  • Dr. Suman M. Verma M.D.
    Ph.D., Chief Scientific Officer
  • Dr. Brian J. deGuzman M.D. (Age 58)
    Chief Compliance Officer
  • Mr. Michael Adam Gordon (Age 49)
    General Counsel & Secretary
  • Michael Parks
    Vice President of Investor Relations














LUCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Lucid Diagnostics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUCD shares.
View LUCD analyst ratings
or view top-rated stocks.

What is Lucid Diagnostics' stock price target for 2024?

2 brokers have issued 1-year price targets for Lucid Diagnostics' stock. Their LUCD share price targets range from $2.50 to $4.00. On average, they expect the company's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 111.0% from the stock's current price.
View analysts price targets for LUCD
or view top-rated stocks among Wall Street analysts.

How have LUCD shares performed in 2023?

Lucid Diagnostics' stock was trading at $1.36 on January 1st, 2023. Since then, LUCD shares have increased by 13.2% and is now trading at $1.54.
View the best growth stocks for 2023 here
.

When is Lucid Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our LUCD earnings forecast
.

How were Lucid Diagnostics' earnings last quarter?

Lucid Diagnostics Inc. (NASDAQ:LUCD) announced its earnings results on Monday, March, 28th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.12. Lucid Diagnostics had a negative trailing twelve-month return on equity of 901.79% and a negative net margin of 4,153.13%.

When did Lucid Diagnostics IPO?

(LUCD) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share.

Who are Lucid Diagnostics' major shareholders?

Lucid Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include LPL Financial LLC (0.07%).
View institutional ownership trends
.

How do I buy shares of Lucid Diagnostics?

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:LUCD) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -